Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: Invir.IO

    Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

    20211109 – Transgene BioInvent SITC BT-001 en

    Published 9 November 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Press release

    Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

    Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002

    Published 16 September 2021
    Categorized as 2021, Invir.IO, Press release, TG6002, TG6002

    Transgene Participates in New Cancer Research Consortium

    Transgene Participates in New Cancer Research Consortium

    Published 1 September 2021
    Categorized as 2021, Press release, Invir.IO, Press release, TG4001, TG4001

    3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses

    Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation

    Published 1 July 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Publication, TG6002, TG6002

    Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)

    20210608 – IP Invir.IO ICI – EN

    Published 8 June 2021
    Categorized as 2021, Invir.IO, Press release

    Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

    210527 – Transgene BioInvent_BT001 IND_EN

    Published 27 May 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Press release

    Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas

    K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation

    Published 9 April 2021
    Categorized as 2021, Invir.IO, Publication, TG6002

    Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences

    20210302 – Transgene Scientific Conferences

    Published 2 March 2021
    Categorized as 2021, Invir.IO, Myvac, Press release

    Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

    20210301 – Transgene BT-001 FPI – EN

    Published 1 March 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Press release

    Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

    20210119 – ANSM Approval BT-001 EN

    Published 19 January 2021
    Categorized as 2021, BT-001, BT-001 (EN), Invir.IO, Press release

    Posts navigation

    Newer posts Page 1 Page 2 … Page 5 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo